Compare Heron Therapeutics Inc (HRTX) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs SiTime Corporation — how do they compare? Heron Therapeutics Inc trades at $0.33 (market cap $63.41M), while SiTime Corporation trades at $680 (market cap $20.73B). The key difference: SiTime Corporation is far larger — about 326.9× Heron Therapeutics Inc's market cap, and SiTime Corporation is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | SITM | |
|---|---|---|
Market Cap | $63.41M | $20.73B |
Sector | Health | Technology |
52-Week High | $1.49 | $901.60 |
52-Week Low | $0.32 | $212.77 |
Enterprise Value | $161.31M | $20.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
SITM stock surged 5.5% to $725.28, showing strong momentum with three consecutive quarterly earnings beats and bullish technical indicators. The company reported 127% revenue growth in Q2 2026 and expects further acceleration from AI infrastructure demand and the Renesas acquisition. Despite negative 2025 earnings, profitability improved significantly with net income turning positive in 2026 projections.
Outlook remains positive with 100% analyst buy ratings and $870 consensus target, though premium valuations (P/E 1,148, P/S 39) and execution risks from the Renesas integration warrant caution. AI timing growth presents substantial opportunity, but stock appears fully valued after recent run-up.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
